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Abstract 
The  human  breast  lobular  and  ductal  structures  and  the  derived  tumors  from  these 
structures differ substantial in their morphology, microenvironment, biological presen-
tation, functions, and clinical prognosis. Based on these differences, we have proposed 
that pre-invasive lobular tumors may progress to invasive lesions through “in situ ma-
lignant transformation”, in which the entire myoepithelial cell layer within a given lobule 
or lobular clusters undergoes extensive degeneration and disruptions, which allows the 
entire epithelial cell population associated with these myoepithelial cell layers directly 
invade the stroma or vascular structures. In contrast, pre-invasive ductal tumors may 
invade the stroma or vascular structures through “progenitor-mediated cell budding”, in 
which  focal  myoepithelial  cell  degeneration-induced  aberrant  leukocyte  infiltration 
causes focal disruptions in the tumor capsules, which selectively favor monoclonal pro-
liferation of the overlying tumor stem cells or a biologically more aggressive cell clone. 
Our current study attempted to provide more direct morphological and immunohisto-
chemical data that are consistent with our hypotheses. 
Key words: Breast cancer; Tumor invasion; Tumor metastasis; Malignant transformation; Tumor 
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Introduction 
The  epithelial  component  of  the  human  breast 
consists  of  lobular  (or  acinar)  cells,  which  are  ar-
ranged as grape-like structures responsible primarily 
for  the  production  of  milk,  and  the  ductal  system, 
which are arranged as branching, three-like structures 
responsible mainly for providing the drainage of the 
secretions [1-3]. Developmentally, the lobular cells are 
derived  from  “budding”  cells  of  the  terminal  ducts 
during the early puberty [4-11]. The lobular cells un-
dergo extensive proliferation, differentiation, molec-
ular  and  biochemical  changes  during  the  entire 
lifespan  of  the  female,  more  notably  during  preg-
nancy and lactation [4-11]. Following menopause, the 
lobular  structures  in  both  nulliparous  and  parous 
women start to regress and a majority of these struc-
tures are eventually replaced by fibrous tissues [4-11]. 
The ductal system starts at the terminal ducts, merges 
into larger ducts, and extends to the nipple orifices. 
Compared to the lobular (acinar) cells, ductal cells are 
relatively more stable during the entire lifetime of the 
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subject [4-11].  
Structurally, the lobular and ductal systems dif-
fer substantially in the following aspects: 
1. The physical distribution and relationship to 
the myoepithelial cells. 
Both the lobular and ductal cells are physically 
separated  from  the  stroma  by  a  layer  of  basement 
membrane  and  a  layer  of  myoepithelial  cells.  The 
basement  membrane  is  structurally  similar  in  both 
lobular and ductal systems. The myoepithelial cells in 
the ductal system generally form a continuous sheet 
that completely encircles all the ducal cells. In con-
trast, the myoepithelail cell layer in the lobular system 
is often discontinuous, defined as the lack of direct 
physical contact or the presence of small gaps (gener-
ally smaller than the size of two myoepithelial cells) 
among  the  neighboring  myoepithelial  cells  [12,13] 
(Fig 1a-1d). 
2. The expression pattern and frequency of 
tumor suppressors in the myoepithelial cell layer 
The myoepithelial cell layer produces a number 
of  tumor  suppressors,  including  maspin,  p63,  and 
Wilms’ tumor 1 (WT-1) that exert significant paracrine 
inhibition on proliferation and invasion of associated 
tumor cells [13-16]. In the normal ductal system, tu-
mor suppressors are consistently expressed in all or 
nearly  all  morphologically  distinct  myoepithelial 
cells. In contrast, many morphologically distinct my-
oepithelial cells in the lobular system are often devoid 
of expression of these established tumor suppressors 
[17-20].  In  some  cases,  many  lobular  clusters  or  an 
entire  lobule  show  no  or  significantly  reduced  ex-
pression  of  p63  and  WT-1  as  compared  to  that  of 
duct-associated [17-20] (Fig 1e-1f). 
3. The expression pattern and frequency of cell 
surface adhesion molecules and c-erbB2 
A  number  of  cell  surface  adhesion  molecules, 
including E-cadherin and ß-catenin, are strongly ex-
pressed in a vast majority of the ductal epithelial cells 
and their malignant derivatives, but are absent in the 
acinar  counterpart,  which,  however,  often  harbors 
isolated lobules with aberrant c-erbB2 expression [21, 
22] (Fig 1g-1j). 
4. The size and length of the lumen.  
The lumen of the lobular units is very small with 
a single open end that leads to the terminal duct. Due 
to this  structural feature, any substantially elevated 
lobular cell proliferation may over-stretch the associ-
ated basement membrane and myoepithelial cell lay-
er, or even physically disrupt these two structures. In 
contrast, the lumen of the ducts is substantially larger 
and intercalated among ducts, which permits a lon-
gitudinal expansion of an increased volume of ductal 
cells and also preserves the physical integrity of the 
surrounding  myoepithelial  cell  layer  and  the  base-
ment membrane. 
Together,  these  structural  features  are  appar-
ently more favorable for proliferation, invasion, and 
metastasis of lobular tumor cells. Consistent with this 
speculation  is  the  fact  that  invasive  lobular  cancers 
(ILC) tend to be significantly larger in size with a sig-
nificantly  higher  rate  of  positive  lymph  nodes  than 
stage-matched  invasive  ductal  carcinoma  (IDC) 
[23-25]. Although large tumor size and positive lymph 
node are two well-recognized risk factors for worse 
prognosis,  patients  with  ILC  have  a  substantially 
more  favorable  clinical  outcomes  compared  to  pa-
tients with IDC [23-27]. These contradictory impacts 
have been largely attributed to the unique features of 
ILC,  including  the  lack  of  E-cadherin  expression, 
higher expression of ER and PR, lower expression of 
HER-2, p53, EGFR, and lower S-phase fraction [28-31]. 
The  trigger  factor  for  the  significant  differences  in 
clinical  outcomes  between  stage-matched  ILC  and 
IDC, however, has not been identified.  
We have hypothesized that the trigger factor for 
the  significant  differences  in  clinical  outcomes  be-
tween  lobular  and  ductal  tumors  may  result  from 
their  substantially  different  growth  patterns  during 
invasion.  As  the  lobular  cell  population  undergoes 
extensive  proliferation  and  differentiation  during 
puberty, pregnancy and lactation [6-11], most adult 
females may have largely exhausted or “used up” the 
residual stem cells, which have been suggested as the 
primary  source  of  invasive  and  metastatic  lesions 
[32-35]. In addition, the extensive proliferation of the 
epithelial  cell  population  during  these  stages  may 
have also caused the exhaustion of the residual stem 
cells in the myoepithelial cell population, which im-
pairs the normal replenishment process, resulting in 
an  aged  myoepithelial  cell  population.  Thus, 
pre-invasive lobular tumors may progress to invasive 
lesions through “in situ malignant transformation”, in 
which  the  entire  myoepithelial  cell  layers  within  a 
given lobule or lobular clusters become degenerated 
and  disrupted,  which  allows  the  entire  tumor  cell 
population to directly invade the stroma. In contrast, 
pre-invasive ductal tumors may invade the stroma or 
vascular  structures  through  “progenitor-mediated  cell 
budding”, in which focal myoepithelial cell degenera-
tion-induced  aberrant  leukocyte  infiltration  causes 
focal disruptions of the tumor capsules, which selec-
tively favor monoclonal proliferation of the overlying 
tumor stem cells or a biologically more aggressive cell  Journal of Cancer 2011, 2 
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clone. Our current study attempted to provide more 
morphological  and  immunohistochemical  data  sup-
portive of our hypothesis.  
Materials and Methods 
Ten  cases  harboring  large  normal  mammary 
ductal  or  acinar  clusters  or  lobules  with  malignant 
features  were  selected  from  our  previous  studies 
[12,13,16-20]. All these samples were retrieved from 
the files of the Armed Forces Institute of Pathology 
with IRB approved protocols. Consecutive sections at 
7-um thickness were cut and placed sequentially on 
positively charged slides. For each case, 300-500 sec-
tions were made. For each set of 10 consecutive sec-
tions, the first 3-4 sections were used for hematoxylin 
and eosin (H & E) staining and immunohistochemis-
try (IHC). The remaining sections were used for var-
ious molecular assays.  
To identify cells with malignancy-associated al-
terations,  sections  were  double  immunostained  for 
p53 (clone: D07, Dako, Carpinteria, CA) and smooth 
muscle actin (SMA; clone: 1A4; Sigma, St. Louis, MO). 
To differentiate between ductal and acinar cells, and 
to identify the potential impact of leukocytes on the 
physical integrity of myoepithelial cell layers, sections 
were  double  immunostained  for  E-cadherin  (clone: 
36B5; Lab Vision, Fremont, CA), and leukocyte com-
mon  antigen  (LCA,  clone:  2B11+PD7/26),  which  is 
present  in  all  normal  hematopoietic  cells  and  their 
neoplastic transformations. To identify disseminated 
or  isolated  epithelial  cells  within  leukocyte  aggre-
gates, sections were double immunostained for LCA 
and cytokeratin (CK) AE1/3 (clone; AE1/AE3, Dako, 
Carpinteria, CA), which are expressed in all epithe-
lium-derived cells.  
 As  our  previous  studies  have  suggested  that 
aberrant leukocyte infiltration could trigger cell dis-
semination and malignant transformation in normal 
appearing lobules [36-40], the possible sign of “in situ 
malignant transformation ” was assessed by examining 
the morphological and immunohistochemical altera-
tions  of  such  lobules  with  infiltrated  leukocyte  ag-
gregates  in  multiple  consecutive  sections,  to  deter-
mine:  (1)  whether  cells  with  malignancy-associated 
changes  can  originate  from  normal  lobules,  (2) 
whether cells with malignancy-associated changes in 
the normal appearing lobules are eventually in phys-
ical  continuity  with  clear-cut  invasive  lesions,  (3) 
whether cells with malignancy-associated changes in 
normal appearing lobules share the same or similar 
morphological  and  immunohistochemical  profile 
with  their  clear-cut  malignant  counterparts,  and  (4) 
whether  leukocyte  aggregates  are  exclusively  or 
preferentially located at or near the intersection be-
tween these lobules and clear-cut invasive lesions.  
 To identify signs of “progenitor-mediated cell bud-
ding”,  the  morphological  and  immunohistochemical 
alterations of hyperplastic or in situ tumors were ex-
amined in cross and longitudinal profile of consecu-
tive sections, to determine: (1) whether morphologi-
cally and immunohistochemically different cell types 
co-exist within the same duct, (2) whether cell “bud-
ding” is exclusively seen at focally disrupted myoep-
ithelial  cell  layers,  (3)  whether  all  “budding”  cells 
share  the  same  morphological  and  immunohisto-
chemical  profile,  (4)  whether  “budding”  cells  are 
eventually in physical continuity with clear-cut inva-
sive  lesions,  (5)  whether  “budding”  cells  share  the 
same morphological and immunohistochemical pro-
file with their clear-cut malignant and invasive coun-
terparts.  
 Immunostaining was carried out using our pub-
lished protocol with monoclonal mouse anti-human 
antibodies.  The  secondary  antibody,  ABC  detection 
kit, and diaminobenzidine (DAB) chromogen kit were 
obtained  from  Vector  (Burlingame,  CA).  The  AP 
red-chromogen  kit  was  purchased  from  Zymad 
(South San Francisco, CA). To assess the specificity of 
the immunostaining, different negative controls were 
used,  including  (1)  the  substitution  of  the  primary 
antibody with the same isotype or pre-immune serum 
of the antibody; and, (2) omission of the secondary 
antibody. Immunostaining procedures were repeated 
at least twice using the same protocol and under the 
same  conditions.  Immunostained  sections  were  in-
dependently evaluated by two investigators. A given 
cell  was  considered  immunoreactive  if  distinct  im-
munoreactivity was consistently seen in its cytoplasm, 
membrane,  or  nucleus,  while  all  negative  controls 
lacked distinct immunostaining.  
Results 
 The  findings  of  our  current  study  are  in  total 
agreement with our hypothesis. Examinations of the 
normal  appearing  lobules  with  infiltrated  leukocyte 
aggregate  consistently  revealed  that:  (1)  cells  with 
malignancy associated changes could originate from 
normal lobules, (2) cells with malignancy associated 
changes  in  the  normal  lobules  were  eventually  in 
physical continuity with clear-cut invasive lesions, (3) 
cells with  malignancy-associated changes  in  normal 
lobules shared the same or similar morphological and 
immunohistochemical profile with their clear-cut ma-
lignant  counterparts,  and  (4)  leukocyte  aggregates 
were almost exclusively located at or near the inter-
section between these lobules and clear-cut invasive 
lesions (Fig 2).   Journal of Cancer 2011, 2 
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Figure 1. Structure differences between lobules and ducts.  Journal of Cancer 2011, 2 
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Figure 2. In situ malignant transformation of lobules.  Journal of Cancer 2011, 2 
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Figure 3. Progenitor-mediated cell budding in mammary ducts.  Journal of Cancer 2011, 2 
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Figure 4. Multiple cell types within mammary ducts. 
 
 
 Examinations of the cross and longitudinal sec-
tion profiles of hyperplastic and in situ breast tumors 
showed that: (1) morphologically and immunohisto-
chemically different cell types co-existed within the 
same duct, (2) cell budding was exclusively seen at 
focally  disrupted  myoepithelial  cell  layers,  (3)  all 
budding  cells  shared  the  same  morphological  and 
immunohistochemical profile, (4) budding cells were 
eventually in physical continuity with clear-cut inva-
sive lesions, and (5) budding cells shared a very sim-
ilar profile with their clear-cut malignant counterparts 
(Figs 3-4). 
Discussion 
 Based on our hypothesis, although the lobular 
cell population has a less suppressive microenviron-
ment and growth advantage, it may retain fewer re-
sidual stem or progenitor cells, compared to its ductal 
counterpart.  Therefore,  lobular  tumors  may  at  a 
greater  risk  for  invasion  or  metastasis,  whereas  the 
invasive or metastatic lobular tumor cells may have 
lower potential to form new tumor nests in new tissue 
sites.  Consequently,  lobular  tumors  may  have  sub-
stantially  more  favorable  prognosis  than  their 
stage-matched ductal counterpart. Our speculation is 
in total agreement with a case control study of 37,692 
ductal  carcinomas  in  situ  (DCIS)  and  4,490  lobular 
carcinoma in situ (LCIS), which showed that patients 
with LCIS were 5.3-fold more likely than patients with 
DCIS  to  develop  invasive  lobular  lesions  [41].  Our 
speculation is also consistent with the pooled data of a 
number  of  epidemiological  studies,  which  have 
shown that although invasive lobular tumors tends to 
be  significantly  larger  in  size  with  a  significantly  Journal of Cancer 2011, 2 
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higher  rate  of  positive  lymph  nodes  than  its 
stage-matched  ductal  counterpart,  patients  with  in-
vasive lobular tumors have a substantially more fa-
vorable  clinical  outcome  [23-27].  Together,  these 
findings suggest the exhaustion or “use-up” the stem 
population  with  a  normal  full  term  pregnancy  or 
multiple pregnancies may represent an effective mean 
to reduce breast cancer risk [32-35].  
 In sharp contrast, as the epithelial component is 
normally devoid of blood vessels and lymphatic ducts 
and totally depends on the stroma for its metabolic 
needs  and  even  survival,  a  focal  myoepithelial  cell 
layer disruption in a given duct could have a number 
of consequences, including: (a) a localized loss or re-
duction of tumor suppressors and the paracrine in-
hibitory functions, which allow the associated tumor 
cells to undergo elevated proliferation [42]; (b) focal 
alterations in the permeability for oxygen, which se-
lectively triggers the exit of stem or progenitor cells 
from  quiescence  [43,44];  (c)  a  localized  increase  of 
leukocyte  infiltration,  which  directly  export  growth 
factors to the associated epithelial cells through direct 
physical  contact  [45-47];  (d)  the  direct  epitheli-
al-stromal  cell  contact,  which  augments  the  expres-
sion of stromal MMP or represses the normal produc-
tion  and  distribution  of  E-cadherin,  and  other  cell 
adhesion  molecules,  facilitating  epitheli-
al-mesenchymal  transition  and  cell  motility  [48-50]; 
(e) the direct exposure of the epithelial cells to differ-
ent cytokines, which stimulate an aberrant expression 
of c-erbB2, which facilitates vasculogenic mimicry and 
tumor angiogenesis [51,52]; and, (f) the direct physical 
contact between newly formed cell clusters and stro-
mal  cells  stimulates  the  production  of  tenascin  and 
other invasion-associated molecules that facilitate the 
stromal tissue remodeling and angiogenesis, provid-
ing a favorable micro-environment for epithelial cell 
proliferation  and  migration  [53,54].  Together,  these 
alterations could selectively favor monoclonal prolif-
eration of the overlying tumor progenitors or a bio-
logically more aggressive cell clone. Thus, the inva-
sive and metastatic cells derived from the duct system 
may have greater potential to form tumor nests in the 
new  tissue  sites,  and  consequently  lead  to  worse 
prognosis. 
If  confirmed,  our  hypothesis  would  have  a 
number of clinical implications. First, the application 
of double immunohistochemistry to identify normal 
appearing  lobular  clusters  with  malignan-
cy-associated alterations and focal myoepithelial cell 
layer disruptions with “budding” tumor cells in clin-
ical biopsies would significantly facilitate early detec-
tion of individuals at greater risk to develop invasive 
cancer or pending invasive lesions. Second, as if two 
independent mechanisms or pathways are responsi-
ble for lobular and ductal cancer invasion, the pre-
cursors of invasive lesions for these tumors are very 
likely  to  differ  substantially  in  their  morphological, 
molecular, and/or biochemical profiles. Consequent-
ly,  micro-dissection  of  these  potential  precursors  of 
invasive  lesions  for  gene  expression  profiling  may 
lead to identification of more specific molecules for 
differentiation  and  intervention  of  invasive  lobular 
and  ductal  cancer.  Third,  as  it  has  been  well  docu-
mented that invasive cancer cells derived from lobu-
lar cancer tend to be more ER (+), PR (+), and HER-2 
(-), compared to their stage-matched ductal counter-
parts  [1-6],  invasive  and  metastatic  lesions  derived 
from  these  tumors  may  have  different  responses  to 
the same therapeutic regimen. Therefore, the devel-
opment of more specific reagents or detection meth-
ods to differentiate lobular and ductal cells and their 
malignant derivatives may have significant therapeu-
tic value. More importantly, as leukocyte aggregates 
have been consistently seen at the junction between 
normal  lobules  harboring  cells  with  malignan-
cy-associated changes and invasive lesions, and also 
at or near focally disrupted myoepithelial cell layers 
with budding tumor cells, anti-inflammatory therapy 
may have significant clinical value for lobular cancers.  
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